Small Molecule API in 2026: Reshoring Challenges and Potent Solutions

Session details:

Small molecule pipelines continue to be robust and increasingly complex and 2026 brings new challenges especially around the need for US-based development and supply options in the current geopolitical, economic and regulatory environment. If you missed JPM Live hear a summary discussion with 3 industry veterans spanning over 50 years of experiences across Merck, DuPont, Wilmington PharmaTech, Sandoz, Lupin, BioDuro and Catalent discuss latest trends and solutions.